These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. Puri P; Sanyal AJ Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052 [TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872 [TBL] [Abstract][Full Text] [Related]
29. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. Utzeri E; Usai P World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650 [TBL] [Abstract][Full Text] [Related]
30. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. Hendrikx T; Schnabl B J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652 [TBL] [Abstract][Full Text] [Related]
32. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642 [TBL] [Abstract][Full Text] [Related]
33. Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet. Mahana D; Trent CM; Kurtz ZD; Bokulich NA; Battaglia T; Chung J; Müller CL; Li H; Bonneau RA; Blaser MJ Genome Med; 2016 Apr; 8(1):48. PubMed ID: 27124954 [TBL] [Abstract][Full Text] [Related]
34. Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. Yamada S; Kamada N; Amiya T; Nakamoto N; Nakaoka T; Kimura M; Saito Y; Ejima C; Kanai T; Saito H BMC Gastroenterol; 2017 Nov; 17(1):136. PubMed ID: 29187142 [TBL] [Abstract][Full Text] [Related]
35. How our understanding of the microbiome has changed the way we look at liver diseases. Adolph TE; Effenberger M; Tilg H Biomark Med; 2018 Nov; 12(11):1203-1206. PubMed ID: 30444134 [No Abstract] [Full Text] [Related]
36. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. van Best N; Jansen PL; Rensen SS Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771 [TBL] [Abstract][Full Text] [Related]
37. NAFLD, Helicobacter species and the intestinal microbiome. Castaño-Rodríguez N; Mitchell HM; Kaakoush NO Best Pract Res Clin Gastroenterol; 2017 Dec; 31(6):657-668. PubMed ID: 29566909 [TBL] [Abstract][Full Text] [Related]
39. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Jiang L; Schnabl B Physiology (Bethesda); 2020 Jul; 35(4):261-274. PubMed ID: 32490750 [TBL] [Abstract][Full Text] [Related]
40. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis]. Bischoff SC Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]